<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the child with bleeding symptoms</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the child with bleeding symptoms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the child with bleeding symptoms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic reviews the approach to evaluating an infant, child, or adolescent presenting with either overt bruising or bleeding or with a history of increased bleeding.</p><p>Thrombocytopenia and specific bleeding disorders, including hemophilia and von Willebrand disease (VWD), are discussed in greater detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia (see  <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia"</a> and  <a class="medical medical_review" href="/z/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children"</a> and  <a class="medical medical_review" href="/z/d/html/4979.html" rel="external">"Neonatal thrombocytopenia: Etiology"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemophilia A and B (see  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a> and  <a class="medical medical_review" href="/z/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis"</a> and  <a class="medical medical_review" href="/z/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VWD (see  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a> and  <a class="medical medical_review" href="/z/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery"</a>)</p><p></p><p>Specific sources of bleeding are also discussed in separate topics:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal bleeding (see  <a class="medical medical_review" href="/z/d/html/5857.html" rel="external">"Approach to upper gastrointestinal bleeding in children"</a> and  <a class="medical medical_review" href="/z/d/html/5904.html" rel="external">"Lower gastrointestinal bleeding in children: Causes and diagnostic approach"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epistaxis (see  <a class="medical medical_review" href="/z/d/html/6451.html" rel="external">"Evaluation of epistaxis in children"</a> and  <a class="medical medical_review" href="/z/d/html/6452.html" rel="external">"Causes of epistaxis in children"</a> and  <a class="medical medical_review" href="/z/d/html/6484.html" rel="external">"Management of epistaxis in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal and/or abnormal uterine bleeding (see  <a class="medical medical_review" href="/z/d/html/15411.html" rel="external">"Evaluation of vulvovaginal bleeding in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/116.html" rel="external">"Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/117.html" rel="external">"Abnormal uterine bleeding in adolescents: Management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bruising that raises concerns for child abuse (see  <a class="medical medical_review" href="/z/d/html/103420.html" rel="external">"Physical child abuse: Recognition"</a> and  <a class="medical medical_review" href="/z/d/html/6600.html" rel="external">"Physical child abuse: Diagnostic evaluation and management"</a>)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>Clinical evaluation of a patient with bleeding symptoms begins with taking a careful history, including the child's age, sex, clinical presentation, personal and family medical history, and medications. Careful attention should be paid to the child's bleeding history, including number and severity of bleeding episodes and characterizing the type of bleeding  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef134983" href="/z/d/graphic/134983.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3645524107"><span class="h2">Bleeding questionnaires</span><span class="headingEndMark"> — </span>Validated bleeding assessment tools (BATs) such as the Pediatric Bleeding Questionnaire (PBQ) and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=5936" target="_blank">International Society on Thrombosis and Haemostasis (ISTH) BAT</a> allow for more objective quantification of bleeding symptoms in pediatric patients [<a href="#rid1">1-3</a>]. Both tools include a nearly identical panel of questions  (<a class="graphic graphic_table graphicRef134983" href="/z/d/graphic/134983.html" rel="external">table 2</a>). They can be used as screening tools to identify patients who are more likely to have an underlying bleeding disorder (ie, those for whom laboratory evaluation may be appropriate). For pediatric patients, a score ≥3 (using either tool) is considered a positive screen. In patients with inherited platelet function defects, a high baseline BAT score is associated with increased risk of future bleeding [<a href="#rid4">4</a>]. BATs have high negative predictive value in children undergoing investigation for von Willebrand disease (VWD; types 1 to 3) [<a href="#rid5">5</a>]. In other words, a child with a low BAT score is unlikely to have VWD. (See  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Personal bleeding history and bleeding assessment tool (BAT)'</a>.)</p><p>A self-administered version of the PBQ is available that uses lay language at a fourth grade reading level rather than medical terminology, making the tool more accessible in clinical practice [<a href="#rid6">6-9</a>]. It has been validated in patients as young as 8 to 12 years of age.</p><p>BATs do not perform as well in the preoperative setting (ie, to identify children at increased risk of surgical bleeding) [<a href="#rid10">10-12</a>]. Nevertheless, if the preoperative history raises concerns for a possible bleeding disorder, it is reasonable to use a BAT to objectively quantify the bleeding symptoms and help determine whether preoperative laboratory testing is warranted. Clinicians should be aware however, that a normal BAT score does not necessarily predict low risk of major bleeding during surgery, nor does an abnormal BAT score accurately predict increased risk of major surgical bleeding [<a href="#rid11">11</a>]. This issue is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1315.html" rel="external">"Preoperative assessment of bleeding risk", section on 'Determine bleeding risk'</a>.)</p><p class="headingAnchor" id="H880215570"><span class="h2">Type of bleeding</span><span class="headingEndMark"> — </span>Bleeding symptoms caused by platelet disorders are quite distinct from those associated with hemophilia or other disorders of coagulation proteins  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding into the skin and mucous membranes is characteristic of disorders of platelets and their interaction with blood vessels and may be manifested as petechiae, ecchymoses, and/or mucosal bleeding  (<a class="graphic graphic_picture graphicRef73905 graphicRef59402 graphicRef71480" href="/z/d/graphic/73905.html" rel="external">picture 1A-C</a>). (See  <a class="medical medical_review" href="/z/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children"</a> and  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding into soft tissue, muscle, and joints suggests the presence of hemophilia or other disorders of coagulation proteins. (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a>.)</p><p></p><p class="headingAnchor" id="H2643919291"><span class="h2">Pathologic versus normal bleeding</span><span class="headingEndMark"> — </span>One important goal of the medical history is to distinguish between a pathologic pattern of bleeding versus normal bleeding symptoms that commonly occur in healthy children.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic bleeding</strong> – The possibility of an underlying bleeding disorder should be considered in children who experience bleeding symptoms that are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unusually frequent</p><p class="bulletIndent2"><span class="glyph">•</span>Long-lasting, or</p><p class="bulletIndent2"><span class="glyph">•</span>Severe</p><p></p><p class="bulletIndent1">In addition, an inherited bleeding disorder should be strongly considered when the onset of bleeding manifestations occurs in infancy or early childhood, particularly if associated with a positive family history.</p><p></p><p class="bulletIndent1">The following are examples of typical presentations suggestive of an underlying bleeding disorder:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A newborn with bleeding from the umbilical stump should be evaluated for coagulation protein defects, including factor XIII deficiency [<a href="#rid13">13</a>]. Intracranial hemorrhage in an infant without other risk factors should also prompt consideration of this diagnosis. (See  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A male infant who is starting to walk and presents with a painful swollen joint after a fall is presumed to have hemophilia until proven otherwise. Similarly, an unusually prominent forehead hematoma ("goose-egg") in a male infant or young male is a common presentation of hemophilia [<a href="#rid14">14</a>], as is excess bleeding after circumcision. (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia", section on 'Initial presentation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An otherwise healthy child who presents with petechiae and/or mucocutaneous purpura in the wake of a viral infection most likely has postinfectious immune thrombocytopenia [<a href="#rid15">15-18</a>]. (See  <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">"Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An adolescent female who presents with excessive menstrual bleeding, recurrent nosebleeds, and pallor may have VWD, the most common inherited bleeding disorder [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1">Clinicians should be alert to the possibility that bruising or bleeding judged to be abnormal (eg, due to frequency, duration, or severity of episodes or lack of explanation for symptoms or physical findings) may be caused by a bleeding disorder or by nonaccidental injury (ie, child abuse). Furthermore, child abuse and bleeding disorders are not mutually exclusive. Therefore, the history should include complete details as to the type of bleeding, location, degree of symptoms, nature of provoking injuries, and whether such injuries are consistent with the child's development and level of activity [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/103420.html" rel="external">"Physical child abuse: Recognition"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding in healthy children</strong> – Bleeding symptoms do occur in healthy children and may not necessarily suggest a generalized bleeding disorder. For example:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Epistaxis may be caused by rhinitis, trauma, superficial vessels, or dry air. However, evaluation for a bleeding disorder may be warranted for children with frequent recurrent nosebleeds, severe nosebleeds that are difficult to control, bilateral nosebleeds, and prior history of bleeding symptoms and/or positive family history [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/6451.html" rel="external">"Evaluation of epistaxis in children"</a> and  <a class="medical medical_review" href="/z/d/html/6452.html" rel="external">"Causes of epistaxis in children"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal postprocedural bleeding (eg, following tonsillectomy, circumcision, tooth extraction) may occur simply due to surgical trauma; however, it may also suggest the possibility of an underlying bleeding disorder, particularly if the child has had a prior history of bleeding symptoms and/or positive family history. (See  <a class="medical medical_review" href="/z/d/html/88054.html" rel="external">"Tonsillectomy (with or without adenoidectomy) in children: Postoperative care and complications", section on 'Hemorrhage'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bruising, particularly of the lower extremities, is common in active toddlers and young children. However, in children with abnormal bruising patterns the possibility of a bleeding disorder or nonaccidental trauma (child abuse) should be considered. The acronym TEN-4-FACESp is commonly used to screen children &lt;4 years of age with bruising to identify when a bruise is more likely to be caused by abuse than accidental injury. TEN-4-FACESp stands for bruising to the <strong>T</strong>orso, <strong>E</strong>ars, or <strong>N</strong>eck; any bruising in an infant ≤<strong>4</strong>.9 months old; <strong>F</strong>renulum tear, bruising on the <strong>A</strong>ngle of the jaw, fleshy <strong>C</strong>heeks, <strong>E</strong>yelids, or <strong>S</strong>ubconjunctivae; or <strong>p</strong>atterned bruising (eg, bites, grip marks, outline of an object) [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/103420.html" rel="external">"Physical child abuse: Recognition", section on 'Inflicted bruises'</a>.)</p><p></p><p class="bulletIndent2">In a study that followed 433 young children with and without bleeding disorders over a period of 12 weeks, children with bleeding disorders had more and larger bruises compared with healthy children, especially at premobile stages of development (ie, nonrolling/rolling over/sitting) [<a href="#rid23">23</a>]. Approximately 50 percent of infants with severe bleeding disorders had bruising noted during premobile stages, whereas bruising was uncommon among healthy premobile infants. Among early mobile (crawling/cruising) and ambulatory children, bruising was common in both groups (&gt;90 percent of children with severe bleeding disorders and 50 to 80 percent of healthy children).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal uterine bleeding is commonly reported by adolescents and can be due to a variety of causes including immaturity of the hypothalamic-pituitary-ovarian axis, other causes of ovulatory dysfunction (eg, polycystic ovary syndrome, thyroid disease), pregnancy-related problems, medications, and infections. Features of abnormal uterine bleeding that are suggestive of an underlying bleeding disorder include heavy menses starting with menarche, presence of iron deficiency anemia, family history of bleeding, other symptoms of bleeding, or failure to respond to first-line treatment of heavy menses [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/116.html" rel="external">"Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Family history</span><span class="headingEndMark"> — </span>The family history is helpful in supporting a possible diagnosis of an inherited disorder of coagulation. The presence of bleeding manifestations only in male siblings and maternal uncles is suggestive of an X-linked recessive disorder, such as hemophilia A or B. However, a negative family history does not exclude an inherited coagulation disorder, as up to one-third of patients with hemophilia have a negative family history [<a href="#rid25">25</a>]. In addition, females carrying the hemophilia gene may also manifest symptoms (eg, heavy menstrual bleeding) [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/1311.html" rel="external">"Genetics of hemophilia A and B", section on 'Transmission'</a>.)</p><p>In contrast, in autosomal dominant disorders such as hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease), an accurate pedigree will show affected male and female family members for several generations [<a href="#rid27">27</a>]. Most instances of VWD are also inherited in an autosomal dominant fashion. In autosomal recessive disorders, such as severe forms of the rarer coagulation factor deficiencies (eg, factor VII or factor XI deficiency), the family history may be negative; consanguinity increases the probability of such disorders [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a> and  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Medications</span><span class="headingEndMark"> — </span>It is important to review any medications that the child is taking, particularly nonsteroidal antiinflammatory drugs (NSAIDs; eg, <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>, <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">naproxen</a>), <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">aspirin</a>, or over-the-counter medications that contain NSAIDs or aspirin. Such drugs impair platelet function and may exacerbate an underlying coagulation disorder. It is important to ask about recent use (ie, within one to two weeks) of these agents even if they are not the suspected cause of the bruising or bleeding in the child because they may cause abnormalities in platelet function tests, which may lead to further unnecessary and expensive studies.</p><p>Less commonly, easy bruising may be attributable to selective serotonin reuptake inhibitors, stimulant medications used to treat attention deficit disorder (eg, as <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">methylphenidate</a>), and oral or topical corticosteroids. All of these agents can lead to easy bruising. (See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Stimulant adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Other effects'</a>.)</p><p>In addition, the clinician should inquire about use of herbal medicines that may contribute to abnormal bleeding (eg, ginger, feverfew, ginkgo biloba, large amounts of garlic) [<a href="#rid29">29-32</a>].</p><p>Accidental or intentional ingestion of <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">warfarin</a> or warfarin-containing rodenticides can also cause bleeding symptoms in children. (See  <a class="medical medical_review" href="/z/d/html/94398.html" rel="external">"Overview of rodenticide poisoning", section on 'Anticoagulants (superwarfarins and warfarins)'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">INITIAL LABORATORY EVALUATION</span></p><p class="headingAnchor" id="H1963852792"><span class="h2">Approach to testing</span><span class="headingEndMark"> — </span>The evaluation for bleeding disorders in children begins with general screening tests that assess hemostasis  (<a class="graphic graphic_table graphicRef80791" href="/z/d/graphic/80791.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef82633" href="/z/d/graphic/82633.html" rel="external">algorithm 2</a>). Based upon the results of these tests and clinical suspicion, additional and more specific testing is performed to narrow the possibilities or make a definitive diagnosis. (See <a class="local">'Diagnostic approach'</a> below and <a class="local">'Additional selective testing'</a> below.)</p><p>For children with clinically significant bleeding symptoms (eg, a score ≥3 using a bleeding assessment tool [BAT]  (<a class="graphic graphic_table graphicRef134983" href="/z/d/graphic/134983.html" rel="external">table 2</a>)) in whom the cause is not readily apparent based upon the history and physical examination, we suggest the following initial tests, which are discussed in the sections below:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count, including platelet count</p><p class="bulletIndent1"><span class="glyph">●</span>Examination of the peripheral blood smear</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT)/international normalized ratio</p><p class="bulletIndent1"><span class="glyph">●</span>Activated partial thromboplastin time (aPTT)</p><p></p><p>At the author's center, we also commonly obtain the following tests as part of the initial evaluation; however, other centers may not include these in the initial testing:</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinogen activity level (see <a class="local">'Fibrinogen'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Testing for von Willebrand disease (VWD) (see <a class="local">'von Willebrand disease testing'</a> below)</p><p></p><p>In most cases, we initially obtain all of these screening tests; however, in certain circumstances, it may be appropriate to perform only limited testing. For example, in an otherwise well child who presents with mucocutaneous bleeding, a complete blood count with platelet count and examination of the peripheral blood smear are the most informative initial tests  (<a class="graphic graphic_algorithm graphicRef82633" href="/z/d/graphic/82633.html" rel="external">algorithm 2</a>).</p><p>Normal values of coagulation tests may vary with age and among different laboratories  (<a class="graphic graphic_table graphicRef66999" href="/z/d/graphic/66999.html" rel="external">table 4</a>). In particular, normal PTs and aPTTs should be based upon an individual clinical laboratory's reference ranges [<a href="#rid33">33</a>]; published ranges should not be used to conclusively ascertain whether an individual result is normal or abnormal.</p><p>Proper collection of the blood sample is essential for interpreting the results of coagulation tests. Blood for coagulation tests should not be drawn from an existing heparinized indwelling line. A cleanly drawn venipuncture sample without air bubbles or tissue fluid contamination is the most appropriate sample for coagulation tests. Coagulation tests are performed on blood anticoagulated with a solution of sodium citrate in a ratio of nine parts of blood to one part of citrate. When the hematocrit is high (eg, newborns and children with cyanotic cardiac disease), the amount of citrate must be adjusted (reduced) to provide the proper ratio [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Sample collection and handling'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Platelet count and the peripheral smear</span><span class="headingEndMark"> — </span>The platelet count is typically performed with an automated cell counter. (See  <a class="medical medical_review" href="/z/d/html/4430.html" rel="external">"Automated complete blood count (CBC)"</a>.)</p><p>Platelets may also be counted directly on the blood smear. Examination of the peripheral blood smear is essential in patients with low platelet counts in order to exclude the presence of pseudothrombocytopenia caused by platelet aggregation after using ethylenediaminetetraacetic acid (EDTA) as an in vitro anticoagulant  (<a class="graphic graphic_picture graphicRef68949" href="/z/d/graphic/68949.html" rel="external">picture 2</a>) [<a href="#rid35">35</a>]. Platelet aggregation causes falsely low platelet counts by the automated cell counter, but the platelet clumps are obvious on examination of the smear. Alternative anticoagulants (eg, trisodium citrate or heparin) may circumvent in vitro EDTA-associated platelet aggregation [<a href="#rid36">36</a>]. Platelet clumping on the smear of a patient with bleeding symptoms may also suggest type 2B VWD or pseudo (platelet type)-VWD  (<a class="graphic graphic_algorithm graphicRef82633" href="/z/d/graphic/82633.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia", section on 'Verification of thrombocytopenia'</a>.)</p><p>Examination of the peripheral smear is important as it may reveal findings that point to an underlying etiology (eg, peripheral blasts  (<a class="graphic graphic_picture graphicRef57831" href="/z/d/graphic/57831.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef65474" href="/z/d/graphic/65474.html" rel="external">picture 4</a>), schistocytes  (<a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">picture 5</a>)). In addition, it permits assessment of platelet size and granularity, which helps to narrow the diagnostic possibilities in a patient with thrombocytopenia  (<a class="graphic graphic_table graphicRef89962" href="/z/d/graphic/89962.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Prothrombin time (PT)</span><span class="headingEndMark"> — </span>The production of fibrin via the extrinsic pathway and the final common pathway requires tissue thromboplastin (tissue factor); factors VII, X, and V; prothrombin (factor II); and fibrinogen. The functioning of these pathways is measured by the PT  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>). This test bypasses the intrinsic pathway and uses "complete" thromboplastins (ie, tissue factor) capable of activating the extrinsic pathway.</p><p>The PT is sensitive to alterations in the vitamin K-dependent coagulation factors, especially factors II, VII, and X. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Prothrombin time (PT) and INR'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Activated partial thromboplastin time (aPTT)</span><span class="headingEndMark"> — </span>The aPTT measures the intrinsic and common pathways of coagulation  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>). It is called "partial" because clotting is initiated in vitro with agents that are only partial thromboplastins (ie, they are incapable of activating the extrinsic pathway). (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Activated partial thromboplastin time (aPTT)'</a>.)</p><p>The aPTT is sensitive to deficiencies of factors XII, XI, IX, and VIII and to inhibitors such as heparin  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>). It is less sensitive than the PT to deficiencies within the common pathway (eg, factors X and V, prothrombin, and fibrinogen) and is unaffected by alterations in factors VII and XIII.</p><p class="headingAnchor" id="H11962280"><span class="h2">Fibrinogen</span><span class="headingEndMark"> — </span>We routinely obtain fibrinogen levels in addition to the PT and aPTT because the three tests together are more sensitive than the PT/aPTT alone for detecting fibrinogen disorders. Mild hypofibrinogenemia (fibrinogen levels between 100 to 150 mg/dL) may not cause prolongation in the PT/aPTT. However, in most cases of severe fibrinogen disorders, the PT and aPTT are both prolonged. Thus, some centers do not routinely obtain fibrinogen levels if the PT and aPTT are normal. (See  <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">"Disorders of fibrinogen"</a>.)</p><p>The functional fibrinogen concentration is typically measured using a sensitized modification of the thrombin time (TT), whereas fibrinogen protein levels are measured using immunologic assays. Immunologic and functional assays of fibrinogen may be discordant in patients with an inherited dysfibrinogenemia (generally with a significantly higher protein level than activity level). Fibrinogen levels reported by most clinical coagulation labs represent functional fibrinogen concentrations.</p><p class="headingAnchor" id="H1419436345"><span class="h2">von Willebrand disease testing</span><span class="headingEndMark"> — </span>Functional assays of VWF binding to platelets or collagen. Though the VWF:RCo assay the quantity and function of von Willebrand factor (VWF). These tests can usually establish whether or not the patient has VWD  (<a class="graphic graphic_algorithm graphicRef131037" href="/z/d/graphic/131037.html" rel="external">algorithm 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>VWF antigen – Quantitative measurement of VWF protein level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VWF activity – Functional assays of VWF binding to platelets or collagen. Though the VWF:RCo assay is the traditional assay used to measure VWF activity, newer tests such as the VWF:GPIbM are generally more reproducible and are becoming widely used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factor VIII activity.</p><p></p><p>The rationale for these tests and the details of their interpretation are summarized in the table  (<a class="graphic graphic_table graphicRef73391" href="/z/d/graphic/73391.html" rel="external">table 6</a>) and discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Laboratory testing'</a>.)</p><p class="headingAnchor" id="H1821313949"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>Results of the initial laboratory testing allow the clinician to narrow the diagnostic possibilities in the child with a bleeding disorder  (<a class="graphic graphic_table graphicRef80791" href="/z/d/graphic/80791.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef82633" href="/z/d/graphic/82633.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H3731400050"><span class="h2">Abnormal blood count</span></p><p class="headingAnchor" id="H1711763410"><span class="h3">Pancytopenia</span><span class="headingEndMark"> — </span>Two important diagnostic considerations in a child with mucocutaneous bleeding and pancytopenia include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukemia</strong> – Other concerning findings that may point to this diagnosis include organomegaly, lymphadenopathy, and/or bone pain. Examination of the peripheral blood smear may reveal the presence of leukemic blasts  (<a class="graphic graphic_picture graphicRef57831" href="/z/d/graphic/57831.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef65474" href="/z/d/graphic/65474.html" rel="external">picture 4</a>), an observation that should be confirmed with a bone marrow examination. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Worrisome findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aplastic anemia</strong> – Children with aplastic anemia present with varying combinations of symptomatic anemia, bleeding, and infection, depending upon the severity of the pancytopenia. Single or multiple skeletal anomalies may be present in children with the congenital forms of aplastic anemia. (See  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3275725665"><span class="h3">Thrombocytopenia</span><span class="headingEndMark"> — </span>Causes of thrombocytopenia in pediatric patients are summarized in the table  (<a class="graphic graphic_table graphicRef61163" href="/z/d/graphic/61163.html" rel="external">table 7</a>). The approach to evaluating children with thrombocytopenia is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia"</a> and  <a class="medical medical_review" href="/z/d/html/4979.html" rel="external">"Neonatal thrombocytopenia: Etiology"</a> and  <a class="medical medical_review" href="/z/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children"</a>.)</p><p class="headingAnchor" id="H3031599104"><span class="h2">Abnormal coagulation tests</span><span class="headingEndMark"> — </span>The results of coagulation studies (prothrombin time [PT], international normalized ratio, activated partial thromboplastin time [aPTT]) may help narrow the diagnostic possibilities  (<a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef80791" href="/z/d/graphic/80791.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H1732122441"><span class="h3">aPTT prolonged/PT normal</span><span class="headingEndMark"> — </span>An isolated prolonged aPTT can be seen in the following conditions  (<a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemophilia A or B</strong> – Hemophilia A (factor VIII deficiency) is the most common inherited disorder yielding a significantly prolonged aPTT. The reported incidence is 1 in 5000 males [<a href="#rid25">25</a>]. Hemophilia B (factor IX deficiency) occurs less often: 1 in 20,000 males. Both disorders have an X-linked recessive transmission and demonstrate a range of presentations depending on severity of the phenotype, ranging from prolonged bleeding after surgery or other trauma to spontaneous soft tissue and joint hemorrhages. Mucocutaneous bleeding (eg, excessive bruising, prolonged oozing from oral wounds) can also occur. Hemophilia carriers, even those with normal factor levels, may have symptoms similar to affected males with mild hemophilia and are at increased risk for reproductive bleeding. (See  <a class="medical medical_review" href="/z/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor XI deficiency</strong> – Factor XI deficiency is seen more commonly in Ashkenazi Jews and presents with a variable history of bleeding, often mucocutaneous in nature [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus anticoagulants</strong> – Lupus anticoagulants are acquired inhibitors (autoantibodies) directed against phospholipid-protein complexes that produce a prolonged aPTT. They are commonly seen in children, frequently associated with recent infections (particularly viral infections), and usually transient. Lupus anticoagulants are <strong>not</strong> associated with bleeding symptoms but rather an increased risk of thrombosis. However, children with transient viral-triggered lupus anticoagulants are generally not at risk for thrombotic complications. (See <a class="local">'Antiphospholipid antibodies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deficiencies of factor XII, high molecular weight kininogen, and prekallikrein</strong> – These disorders are typically asymptomatic and not associated with clinical bleeding. Patients with these deficiencies are often discovered when an asymptomatic child demonstrates a significantly prolonged aPTT on routine preoperative screening. Although such a deficiency may hold little clinical consequence, it can be important to identify since it provides an explanation for an otherwise puzzling prolonged aPTT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin contamination</strong> – Blood drawn from heparin-containing intravascular lines is another cause of isolated aPTT prolongation. This possibility can generally be excluded by obtaining a fresh blood sample from a venipuncture stick. Heparin contamination can also be confirmed by measuring the thrombin time (TT) and reptilase time (RT; the former will be prolonged, while the latter will be normal); however, this is not commonly done in clinical practice. (See <a class="local">'Thrombin time and reptilase time'</a> below.)</p><p></p><p class="headingAnchor" id="H4209196080"><span class="h3">PT prolonged/aPTT normal</span><span class="headingEndMark"> — </span>An isolated prolonged PT is characteristic of  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a> and <a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inherited factor VII deficiency</strong>, which displays phenotypic and molecular heterogeneity (see  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired factor VII inhibitors</strong>, which are very rare occurrences during childhood [<a href="#rid38">38</a>] (see  <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)", section on 'Factor VII inhibitors'</a>)</p><p></p><p class="headingAnchor" id="H192890733"><span class="h3">PT and aPTT both prolonged</span></p><p class="headingAnchor" id="H2253233240"><span class="h4">Well child</span><span class="headingEndMark"> — </span>Prolongation of both PT and aPTT in a child with bleeding symptoms but who is otherwise well indicates an inherited disorder within the common pathway or an acquired disorder involving multiple pathways  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a> and <a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a>).</p><p>Inherited deficiencies in this category include deficiency of factors X, V, and II; (prothrombin); or fibrinogen. These deficiencies are rare. (See  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a>.)</p><p>Inherited disorders of fibrinogen (hypo- or afibrinogenemia) are autosomal recessive disorders, and bleeding associated with these disorders is treatable with cryoprecipitate or fibrinogen concentrates. Dysfibrinogenemia, an autosomal dominant disorder, may be associated with either bleeding or excessive clotting. (See  <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">"Disorders of fibrinogen"</a>.)</p><p class="headingAnchor" id="H1430088605"><span class="h4">Sick child</span><span class="headingEndMark"> — </span>In a sick child with prolongation of both PT and aPTT, disorders to consider are disseminated intravascular coagulation (DIC; eg, due to sepsis or other systemic illness), severe liver disease, or severe vitamin K deficiency  (<a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a>). The factor V level can be used to distinguish between vitamin K deficiency and liver disease or DIC (it is normal in the former and decreased in the latter two conditions). (See  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.)</p><p>Other rare causes of prolonged PT and aPTT in an ill-appearing child include major vessel thrombosis, as well as consumption coagulopathy in certain vascular lesions.</p><p>Accidental or intentional ingestion of <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">warfarin</a> or warfarin-containing rodenticides sufficient to cause bleeding usually results in a prolongation of the PT and aPTT because the vitamin K-dependent factors that are inhibited by warfarin are present in the extrinsic (factor VII), intrinsic (factor IX), and common pathways (factors II and X)  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>) [<a href="#rid39">39</a>]. Hemorrhage under such circumstances may be life-threatening and requires immediate treatment with combinations of intravenous vitamin K, fresh frozen plasma, and/or prothrombin complex concentrates (which contain all of the vitamin K-dependent coagulation factors). (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Treatment of bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/94398.html" rel="external">"Overview of rodenticide poisoning", section on 'Anticoagulants (superwarfarins and warfarins)'</a>.)</p><p>There have been rare case reports of acquired inhibitors to prothrombin, factor V, and factor X. (See  <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)"</a>.)</p><p class="headingAnchor" id="H3908856695"><span class="h3">Abnormal von Willebrand disease testing</span><span class="headingEndMark"> — </span>von Willebrand disease (VWD) is the most common inherited bleeding disorder. There are three major types of VWD. Types 1 and 3 are quantitative deficiencies of von Willebrand factor (VWF), whereas type 2 is a qualitative disorder. (See  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a>.)</p><p>Laboratory tests for VWD include VWF antigen, VWF activity, and factor VIII activity  (<a class="graphic graphic_algorithm graphicRef131037" href="/z/d/graphic/131037.html" rel="external">algorithm 3</a>). The platelet count may be low in some patients with type 2B VWD. (See  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Laboratory testing'</a>.)</p><p>The laboratory diagnosis of VWD in pediatric patients is complicated by VWF assay variability and stress-induced elevations in VWF levels. Patients with a high suspicion of VWD who have borderline initial laboratory results should undergo repeat testing. In a retrospective cohort of 811 patients undergoing evaluation for a suspected bleeding disorder, 22 percent were ultimately diagnosed with VWD, of whom approximately 30 percent required repeat testing to make the diagnosis [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Repeat testing in individuals with borderline or discordant clinical and laboratory findings'</a>.)</p><p class="headingAnchor" id="H225730022"><span class="h2">Normal initial testing</span><span class="headingEndMark"> — </span>In children with bleeding symptoms and a normal initial laboratory screen, possible diagnoses include some cases of hemophilia, factor XIII deficiency, platelet function disorders, vascular anomalies, connective tissue disorders, and fibrinolytic disorders. In addition, some patients with VWD may have equivocal or borderline results on initial testing, as discussed above. (See <a class="local">'Abnormal von Willebrand disease testing'</a> above.)</p><p class="headingAnchor" id="H3472306915"><span class="h3">Some cases of hemophilia</span><span class="headingEndMark"> — </span>Mild cases of hemophilia B, in which factor IX activity is in the 6 to 40 percent range, may not reliably result in prolongation of the aPTT on initial hemostatic screening, due to relative insensitivity of aPTT reagents to mild factor IX deficiency. In addition, there exist uncommon forms of hemophilia A in which factor VIII deficiency may be undetectable on the typical, one-stage, aPTT-based assay used in the majority of laboratories worldwide [<a href="#rid41">41</a>]. In such cases, a mild "discrepant" form of hemophilia A may only be recognized with use of special two-stage or chromogenic assays of factor VIII activity [<a href="#rid42">42</a>]. When there is a high clinical suspicion for an underlying bleeding disorder but the initial coagulation tests are normal, these diagnoses can be ruled out by specific testing of factor IX activity and a two-stage or chromogenic assay of factor VIII activity, respectively. Carriers of the hemophilia gene may also experience bleeding symptoms in the setting of normal factor levels and normal aPTT. (See <a class="local">'Specific factor deficiencies and inhibitors'</a> below.) </p><p class="headingAnchor" id="H421614436"><span class="h3">Factor XIII deficiency and other fibrinolytic disorders</span><span class="headingEndMark"> — </span>Activated factor XIII is responsible for clot stabilization and crosslinking of fibrin polymer  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>). Factor XIII deficiency is not detected by prolongation of either PT or aPTT since neither assay measures the mechanical strength or stability of the fibrin clot.</p><p>Inherited factor XIII deficiency is an autosomal recessive disorder characterized by reduced clot stability and abnormal bleeding. One of the characteristic abnormalities of factor XIII deficiency is delayed separation of the umbilical cord and delayed bleeding from the umbilical stump. In the neonatal period, intracranial hemorrhage with little or no trauma and poor wound healing also are associated with the deficiency. Evaluation and management of factor XIII deficiency are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders", section on 'Factor XIII deficiency (F13D)'</a>.)</p><p>If factor XIII deficiency is suspected, the quantitative assay should be performed [<a href="#rid13">13</a>]. (See <a class="local">'Clot solubility in urea and factor XIII activity testing'</a> below.)</p><p>Deficiencies of alpha-2-antiplasmin and plasminogen activator inhibitor have also been associated with an increased bleeding tendency. (See  <a class="medical medical_review" href="/z/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis", section on 'Alpha-2-antiplasmin deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis", section on 'PAI-1 deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis", section on 'Alpha-2-antiplasmin'</a>.)</p><p class="headingAnchor" id="H2471780732"><span class="h3">Platelet function disorders</span><span class="headingEndMark"> — </span>Studies to confirm the presence of qualitative disorders of platelet function include evaluation of platelet morphology on the peripheral blood smear, tests of platelet aggregation, and other tests of platelet function [<a href="#rid43">43,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing"</a>.)</p><p>Acquired causes of abnormal platelet function are much more common than inherited causes and include use of certain medications (eg, <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">aspirin</a>, nonsteroidal antiinflammatory drugs [NSAIDS]), uremia, and the myeloproliferative and myelodysplastic syndromes. As noted above, it is critical to ascertain a history of ingestion of NSAIDs or other platelet inhibitors in any patient with a bleeding disorder. In addition, if platelet function tests are to be performed (eg, platelet function analyzer [PFA]-100, platelet aggregation studies), the subject must refrain from taking these drugs prior to testing. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'Caveats with testing'</a>.)</p><p>Classic inherited disorders of platelet function are relatively rare and include  (<a class="graphic graphic_table graphicRef69518" href="/z/d/graphic/69518.html" rel="external">table 8</a>) (see  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Glanzmann thrombasthenia – Characterized by a defect in the platelet glycoprotein IIb/IIIa complex that normally upon platelet activation functions as the fibrinogen receptor, mediating platelet aggregation by enabling crosslinking between platelets and fibrinogen. Affected children present with significant mucocutaneous bleeding and a normal platelet count but highly abnormal platelet aggregation (absent or decreased aggregation to adenosine phosphate, epinephrine, collagen, and thrombin but normal aggregation to ristocetin) [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Glanzmann thrombasthenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bernard-Soulier syndrome – Characterized by a defect in one of the components of the platelet glycoprotein Ib-IX-V complex, giant platelets, and bleeding that is greater than expected for the degree of thrombocytopenia [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Bernard-Soulier syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Storage pool diseases – Hermansky-Pudlak syndrome and Chediak-Higashi syndrome are characterized by deficiency of delta-granule platelet storage pools. Milder and less specific forms of platelet storage pool disorders, such as alpha-granule deficiency (gray platelet syndrome), are more common than these two rare syndromes [<a href="#rid47">47</a>]. These are readily identifiable by specific platelet morphologic changes on the peripheral blood smear. (See  <a class="medical medical_review" href="/z/d/html/115158.html" rel="external">"Hermansky-Pudlak syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3926.html" rel="external">"Chediak-Higashi syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Chediak-Higashi syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other platelet function disorders – Platelet function testing in patients undergoing evaluation of mucocutaneous bleeding frequently identifies abnormalities that are less well characterized than for the classic disorders described above. These nonspecific platelet function defects are quite common and should be tested for concurrent with or soon after testing for VWD [<a href="#rid43">43,44</a>].</p><p></p><p class="headingAnchor" id="H4162864499"><span class="h3">Vascular purpuras</span><span class="headingEndMark"> — </span>Screening tests usually are normal in patients with bleeding disorders related to vascular abnormalities. (See  <a class="medical medical_review" href="/z/d/html/141392.html" rel="external">"Purpuric skin lesions (petechiae, purpura, and ecchymoses) in children: Causes", section on 'Disruptions in vascular integrity'</a>.)</p><p>These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Structural vascular abnormalities (eg, hereditary hemorrhagic telangiectasia) (see  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary disorders of connective tissue (eg, Ehlers-Danlos disease and osteogenesis imperfecta) (see  <a class="medical medical_review" href="/z/d/html/14920.html" rel="external">"Clinical manifestations and diagnosis of Ehlers-Danlos syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/2943.html" rel="external">"Osteogenesis imperfecta: An overview"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acquired connective tissue disorders (eg, scurvy, steroid-induced purpura) (see  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Dermatologic effects and appearance'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small vessel vasculitis (eosinophilic granulomatosis with polyangiitis [Churg-Strauss], immunoglobulin A vasculitis [Henoch-Schönlein purpura], microscopic polyangiitis, or granulomatosis with polyangiitis) (see  <a class="medical medical_review" href="/z/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychogenic purpura (see  <a class="medical medical_review" href="/z/d/html/1343.html" rel="external">"Psychogenic purpura (Gardner-Diamond syndrome)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purpura associated with the presence of paraproteins</p><p></p><p class="headingAnchor" id="H2774191591"><span class="h3">Bleeding of unknown cause</span><span class="headingEndMark"> — </span>A subset of patients with mild to moderate bleeding tendencies have no abnormalities in clinically available laboratory assays [<a href="#rid48">48</a>]. The term "bleeding of unknown cause" is often used as a diagnosis for such patients. Studies in which extensive specialized testing was performed for patients in this category have demonstrated impairments in thrombin-generating potential, clot formation, and fibrinolysis [<a href="#rid48">48-50</a>].</p><p>Physical abuse of the child should be considered in such cases. (See  <a class="medical medical_review" href="/z/d/html/6600.html" rel="external">"Physical child abuse: Diagnostic evaluation and management"</a>.)</p><p class="headingAnchor" id="H2624487761"><span class="h1">ADDITIONAL SELECTIVE TESTING</span><span class="headingEndMark"> — </span>Based upon the results of the initial tests, additional testing may be performed to narrow the possibilities or make a definitive diagnosis. The approach to the diagnostic evaluation is reviewed above. (See <a class="local">'Diagnostic approach'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h2">Specific factor deficiencies and inhibitors</span><span class="headingEndMark"> — </span>An abnormally prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT) can be due to the absence or reduced concentration of a coagulation factor or the presence of an inhibitor to one of the coagulation factors:</p><p class="bulletIndent1"><span class="glyph">●</span>A factor deficiency should be correctable by the addition of normal plasma ("mixing study"). This normally is performed by repeating the abnormal PT or aPTT with a 1:1 mixture of patient and normal plasma. If the 1:1 mixture corrects the abnormal test, a deficiency of a coagulation factor is likely to be present. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Evaluation of abnormal results'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a factor inhibitor is suspected when the abnormal test does not correct, or only partially corrects, after immediate assay of a 1:1 mixture of patient and normal plasma. (See  <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)", section on 'Laboratory testing'</a>.)</p><p></p><p>Deficiencies of specific factors may be determined by assessing the PT or aPTT in mixtures of patient plasma with commercially available plasma deficient in known factors. Factor levels can be assessed functionally by comparing test results with standard curves generated by mixtures of serially diluted normal plasma and factor-deficient plasma. Immunologic assays also can be used to measure factor protein levels. Immunologic and functional assays should give equivalent results when a quantitative factor deficiency is present (generally referred to as "type 1 deficiency"). Reduction in a functional assay with a normal immunologic assay suggests the presence of a functionally abnormal factor ("type 2 deficiency").</p><p class="headingAnchor" id="H2659563855"><span class="h2">Platelet function testing</span><span class="headingEndMark"> — </span>In addition to the evaluation of platelet count and morphology by examination of the peripheral blood smear, different tests are available that evaluate platelet function  (<a class="graphic graphic_table graphicRef138645" href="/z/d/graphic/138645.html" rel="external">table 9</a>). Testing is challenging because some tests are highly operator-dependent, many tests are poorly standardized and poorly reproducible, and no test assesses all aspects of platelet function. When platelet function testing is performed, it generally should be carried out in consultation with a hematologist. Platelet aggregation testing should be performed in specialized laboratories with expertise in their methods and interpretation.</p><p>The following sections briefly summarize a few of the available platelet function tests. These and other platelet function tests are discussed in greater detail separately (see  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet function analyzer (PFA-100)</strong> – The PFA-100 is a simple, rapid test that can be performed at the point of care to measure global platelet function. Because of its simplicity, it is sometimes used as a screening tool for platelet function defects and von Willebrand disease (VWD) in children [<a href="#rid51">51,52</a>]. However, it is neither sensitive nor specific for any particular disorder and its optimal use in clinical practice remains uncertain. The PFA-100 is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'PFA-100'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet aggregation</strong> – Traditional platelet aggregation assays measure platelet activation and aggregation in vitro in response to various known platelet agonists (eg, adenosine diphosphate [ADP], arachidonic acid, collagen, epinephrine, thrombin, and ristocetin). Either whole blood or platelet-rich plasma is used depending on the technique. Since many common medications can affect platelet function, care must be taken to avoid their use in patients prior to testing. Expected aggregation results with specific platelet disorders are summarized in the table  (<a class="graphic graphic_table graphicRef69518" href="/z/d/graphic/69518.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'Platelet aggregometry'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboelastography (TEG) and rotational thromboelastometry (ROTEM)</strong> – TEG and ROTEM assess platelet-mediated thrombin formation. These tests are uncommonly used in the evaluation of children with bleeding symptoms. They are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'Viscoelastic testing (TEG and ROTEM)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding time</strong> – The bleeding time is <strong>not</strong> performed routinely as a screening test in children (or adults), because it is poorly reproducible, invasive, insensitive, and time consuming. A normal bleeding time does not predict the safety of surgical procedures, nor does an abnormal bleeding time predict for excessive surgical bleeding. It is not recommended as a preoperative screening test. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'Tests not commonly used'</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Antiphospholipid antibodies</span><span class="headingEndMark"> — </span>Antiphospholipid antibodies (aPL) are not typically associated with bleeding symptoms (to the contrary, they are associated with increased thrombotic risk). However, they can be associated with prolongation of the aPTT that is not correctable by the addition of normal plasma. Thus, testing for aPL can be helpful in patients with a prolonged aPTT that is not otherwise explained. The effect of aPL on the aPTT can be partially overcome by adding excess platelet phospholipid or by assessing the diluted Russell viper venom time [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'dRVVT'</a> and  <a class="medical medical_review" href="/z/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'Antiphospholipid antibody testing'</a>.)</p><p class="headingAnchor" id="H3578525313"><span class="h2">Thrombin time and reptilase time</span><span class="headingEndMark"> — </span>The thrombin time (TT) and reptilase time (RT) measure the final step of coagulation: the conversion of fibrinogen to fibrin  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>). The TT is performed by incubating citrated plasma in the presence of dilute thrombin, measuring the time to clot formation. Reptilase, a thrombin-like enzyme obtained from snake venom, differs from thrombin in that it resists inhibition by heparin via antithrombin III.</p><p>These tests may be used in the following settings (see  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Thrombin time (TT)'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>To evaluate patients with otherwise unexplained prolonged PT and aPTT. (See <a class="local">'PT and aPTT both prolonged'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To detect heparin in a sample – Simultaneous measurement of TT and RT is useful in this setting since heparin prolongs the former but not the latter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To evaluate for an inherited fibrinogen disorder. (See  <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">"Disorders of fibrinogen", section on 'Heritable (genetic) disorders'</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Clot solubility in urea and factor XIII activity testing</span><span class="headingEndMark"> — </span>The initial immature fibrin clot, held together by noncovalent bonds, is soluble in urea. Subsequent transglutamination within the clot by activated factor XIIIa covalently crosslinks overlapping fibrin strands, which then are resistant to solubilization by urea  (<a class="graphic graphic_figure graphicRef79998" href="/z/d/graphic/79998.html" rel="external">figure 1</a>). The ability of urea to solubilize the mature clot reflects a severe deficiency of factor XIII [<a href="#rid13">13</a>]. However, the clot solubility assay is sensitive only at very low levels (factor XIII 1 to 3 percent) and may miss the diagnosis in less severe cases. Therefore, if factor XIII deficiency is suspected, specific quantitative assays are recommended. (See  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Tests for fibrinolysis</span><span class="headingEndMark"> — </span>Fibrin and fibrinogen degradation products are protein fragments resulting from the action of plasmin on fibrin or fibrinogen, respectively  (<a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">figure 2</a>). Elevated levels are seen in states of fibrinolysis such as DIC. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Clot dissolution and fibrinolysis'</a> and  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.)</p><p class="headingAnchor" id="H1467928090"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112393.html" rel="external">"Society guideline links: Hemophilia A and B"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119323.html" rel="external">"Society guideline links: von Willebrand disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119326.html" rel="external">"Society guideline links: Rare inherited bleeding disorders"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119328.html" rel="external">"Society guideline links: Acquired bleeding disorders"</a>.)</p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – The evaluation of a child with abnormal bleeding begins with a focused history, including the clinical presentation, medical history, family history, and medications. (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bleeding questionnaires (eg, the International Society on Thrombosis and Haemostasis bleeding assessment tool [ISTH BAT]) can be useful for assessing the bleeding history  (<a class="graphic graphic_table graphicRef134983" href="/z/d/graphic/134983.html" rel="external">table 2</a>). (See <a class="local">'Bleeding questionnaires'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mucocutaneous bleeding into the skin and mucous membranes is characteristic of platelet disorders, while muscle, joint, and soft tissue bleeding is characteristic of coagulation disorders  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a>). (See <a class="local">'Type of bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The nature and extent of the injuries producing bleeding symptoms should be noted. Clinicians should be alert to the possibility of child abuse as a potential cause of abnormal bruising or bleeding. (See  <a class="medical medical_review" href="/z/d/html/103420.html" rel="external">"Physical child abuse: Recognition"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial laboratory evaluation</strong> – We suggest the following initial laboratory evaluation for children with clinically significant bleeding symptoms (eg, a score of ≥3 on the ISTH BAT  (<a class="graphic graphic_table graphicRef134983" href="/z/d/graphic/134983.html" rel="external">table 2</a>)) when the cause is not readily apparent based upon the history and physical examination (see <a class="local">'Initial laboratory evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count (including platelet count)</p><p class="bulletIndent2"><span class="glyph">•</span>Examination of the peripheral blood smear</p><p class="bulletIndent2"><span class="glyph">•</span>Prothrombin time (PT)</p><p class="bulletIndent2"><span class="glyph">•</span>Activated partial thromboplastin time (aPTT)</p><p class="bulletIndent2"><span class="glyph">•</span>Fibrinogen level</p><p class="bulletIndent2"><span class="glyph">•</span>Screening tests for von Willebrand disease (VWD), including von Willebrand factor (VWF) antigen, VWF activity, and factor VIII activity  (<a class="graphic graphic_algorithm graphicRef131037" href="/z/d/graphic/131037.html" rel="external">algorithm 3</a>)</p><p></p><p class="bulletIndent1">Normal values for coagulation assays may vary with age and among different laboratories  (<a class="graphic graphic_table graphicRef66999" href="/z/d/graphic/66999.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic approach</strong> – The results of the initial testing help differentiate among the different diagnostic possibilities, as summarized in the table and algorithms  (<a class="graphic graphic_table graphicRef80791" href="/z/d/graphic/80791.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef60745" href="/z/d/graphic/60745.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef82633" href="/z/d/graphic/82633.html" rel="external">algorithm 2</a>) and discussed in detail above. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing</strong> – Based upon the results of the initial tests, additional testing may be performed to narrow the possibilities or make a definitive diagnosis. Depending on the clinical circumstances, such testing may include tests for specific factor deficiencies, platelet function tests, testing for antiphospholipid antibodies (aPL), thrombin time (TT), factor XIII activity, and tests for fibrinolysis. (See <a class="local">'Additional selective testing'</a> above.)</p><p></p><p class="headingAnchor" id="H3206043505"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Donald Yee, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bowman M, Riddel J, Rand ML, et al. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7:1418.</a></li><li><a class="nounderline abstract_t">Biss TT, Blanchette VS, Clark DS, et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8:950.</a></li><li><a class="nounderline abstract_t">Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8:2063.</a></li><li><a class="nounderline abstract_t">Gresele P, Falcinelli E, Bury L, et al. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost 2021; 19:1364.</a></li><li><a class="nounderline abstract_t">Moenen FCJI, Nelemans PJ, Schols SEM, et al. The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: A systematic review. Haemophilia 2018; 24:525.</a></li><li><a class="nounderline abstract_t">Deforest M, Grabell J, Albert S, et al. Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease. Haemophilia 2015; 21:e384.</a></li><li><a class="nounderline abstract_t">Casey LJ, Tuttle A, Grabell J, et al. Generation and optimization of the self-administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Bui J, Martyres D, James PD, et al. Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years. Pediatr Blood Cancer 2019; 66:e27709.</a></li><li><a class="nounderline abstract_t">Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia 2021; 27:710.</a></li><li><a class="nounderline abstract_t">Ambaglio C, Zane F, Russo MC, et al. Preoperative bleeding risk assessment with ISTH-BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study. Haemophilia 2021; 27:717.</a></li><li><a class="nounderline abstract_t">Sim AY, Bowman M, Hopman W, et al. Predicting operative bleeding in elective pediatric surgeries using the Pediatric Bleeding Questionnaire (PBQ). J Pediatr Hematol Oncol 2014; 36:e246.</a></li><li><a class="nounderline abstract_t">Guay J, Faraoni D, Bonhomme F, et al. Ability of hemostatic assessment to detect bleeding disorders and to predict abnormal surgical blood loss in children: a systematic review and meta-analysis. Paediatr Anaesth 2015; 25:1216.</a></li><li><a class="nounderline abstract_t">Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14:1190.</a></li><li><a class="nounderline abstract_t">Plummer ES, Crary SE, Buchanan GR. Prominent forehead hematomas ("goose-eggs") as an initial manifestation of hemophilia. J Pediatr 2013; 163:1781.</a></li><li><a class="nounderline abstract_t">Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program 2018; 2018:405.</a></li><li><a class="nounderline abstract_t">Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.</a></li><li><a class="nounderline abstract_t">Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168.</a></li><li><a class="nounderline abstract_t">Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am 2010; 24:249.</a></li><li><a class="nounderline abstract_t">O'Brien SH, Saini S. von Willebrand Disease in Pediatrics: Evaluation and Management. Hematol Oncol Clin North Am 2019; 33:425.</a></li><li><a class="nounderline abstract_t">Khair K, Liesner R. Bruising and bleeding in infants and children--a practical approach. Br J Haematol 2006; 133:221.</a></li><li><a class="nounderline abstract_t">Stokhuijzen E, Segbefia CI, Biss TT, et al. Severity and Features of Epistaxis in Children with a Mucocutaneous Bleeding Disorder. J Pediatr 2018; 193:183.</a></li><li><a class="nounderline abstract_t">Pierce MC, Kaczor K, Lorenz DJ, et al. Validation of a Clinical Decision Rule to Predict Abuse in Young Children Based on Bruising Characteristics. JAMA Netw Open 2021; 4:e215832.</a></li><li><a class="nounderline abstract_t">Collins PW, Hamilton M, Dunstan FD, et al. Patterns of bruising in preschool children with inherited bleeding disorders: a longitudinal study. Arch Dis Child 2017; 102:1110.</a></li><li><a class="nounderline abstract_t">James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201:12.e1.</a></li><li><a class="nounderline abstract_t">Bertamino M, Riccardi F, Banov L, et al. Hemophilia Care in the Pediatric Age. J Clin Med 2017; 6.</a></li><li><a class="nounderline abstract_t">van Galen KPM, d'Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost 2021; 19:1883.</a></li><li><a class="nounderline abstract_t">Kühnel T, Wirsching K, Wohlgemuth W, et al. Hereditary Hemorrhagic Telangiectasia. Otolaryngol Clin North Am 2018; 51:237.</a></li><li><a class="nounderline abstract_t">Napolitano M, Siragusa S, Mariani G. Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy. J Clin Med 2017; 6.</a></li><li><a class="nounderline abstract_t">Ghauri AJ, Abbott J, Shah P, Gardiner P. Bleeding risks associated with herbal medicine in children. Glob Adv Health Med 2014; 3:5.</a></li><li class="breakAll">Schulman S. World Federation of Hemophilia. Drugs that can cause bleeding. 2010. Available at: www.wfh.org/en/page.aspx?pid=639 (Accessed on August 26, 2019).</li><li><a class="nounderline abstract_t">Hatfield J, Saad S, Housewright C. Dietary supplements and bleeding. Proc (Bayl Univ Med Cent) 2022; 35:802.</a></li><li><a class="nounderline abstract_t">Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38:865.</a></li><li><a class="nounderline abstract_t">Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95:362.</a></li><li><a class="nounderline abstract_t">Marlar RA, Potts RM, Marlar AA. Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values. Am J Clin Pathol 2006; 126:400.</a></li><li><a class="nounderline abstract_t">Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984; 59:123.</a></li><li><a class="nounderline abstract_t">Lippi U, Schinella M, Nicoli M, et al. EDTA-induced platelet aggregation can be avoided by a new anticoagulant also suitable for automated complete blood count. Haematologica 1990; 75:38.</a></li><li><a class="nounderline abstract_t">Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia 2008; 14:1183.</a></li><li><a class="nounderline abstract_t">Perry DJ. Factor VII Deficiency. Br J Haematol 2002; 118:689.</a></li><li><a class="nounderline abstract_t">Chua JD, Friedenberg WR. Superwarfarin poisoning. Arch Intern Med 1998; 158:1929.</a></li><li><a class="nounderline abstract_t">Doshi BS, Rogers RS, Whitworth HB, et al. Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients. J Thromb Haemost 2019; 17:1838.</a></li><li><a class="nounderline abstract_t">Park CH, Seo JY, Kim HJ, et al. A diagnostic challenge: mild hemophilia B with normal activated partial thromboplastin time. Blood Coagul Fibrinolysis 2010; 21:368.</a></li><li><a class="nounderline abstract_t">Duncan EM, Rodgers SE, McRae SJ. Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays. Semin Thromb Hemost 2013; 39:272.</a></li><li><a class="nounderline abstract_t">Hayward CP. Diagnostic approach to platelet function disorders. Transfus Apher Sci 2008; 38:65.</a></li><li><a class="nounderline abstract_t">Israels SJ, Kahr WH, Blanchette VS, et al. Platelet disorders in children: A diagnostic approach. Pediatr Blood Cancer 2011; 56:975.</a></li><li><a class="nounderline abstract_t">Poon MC, Di Minno G, d'Oiron R, Zotz R. New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfus Med Rev 2016; 30:92.</a></li><li><a class="nounderline abstract_t">Andrews RK, Berndt MC. Bernard-Soulier syndrome: an update. Semin Thromb Hemost 2013; 39:656.</a></li><li><a class="nounderline abstract_t">Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99:253.</a></li><li><a class="nounderline abstract_t">Gebhart J, Hofer S, Panzer S, et al. High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB). Haemophilia 2018; 24:405.</a></li><li><a class="nounderline abstract_t">Hofer S, Ay C, Rejtö J, et al. Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause. J Thromb Haemost 2019; 17:1478.</a></li><li><a class="nounderline abstract_t">Mehic D, Pabinger I, Ay C, Gebhart J. Fibrinolysis and bleeding of unknown cause. Res Pract Thromb Haemost 2021; 5:e12511.</a></li><li><a class="nounderline abstract_t">Ardillon L, Ternisien C, Fouassier M, et al. Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year 'real-world' experience. Haemophilia 2015; 21:646.</a></li><li><a class="nounderline abstract_t">Podda GM, Bucciarelli P, Lussana F, et al. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007; 5:2393.</a></li><li><a class="nounderline abstract_t">Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7:1737.</a></li></ol></div><div id="topicVersionRevision">Topic 5936 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19496919" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20136710" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20626619" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33880867" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29873431" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26179127" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28453185" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Generation and optimization of the self-administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30900820" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34089545" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34265124" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preoperative bleeding risk assessment with ISTH-BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23774159" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predicting operative bleeding in elective pediatric surgeries using the Pediatric Bleeding Questionnaire (PBQ).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26467201" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ability of hemostatic assessment to detect bleeding disorders and to predict abnormal surgical blood loss in children: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19141159" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Factor XIII deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23968747" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prominent forehead hematomas ("goose-eggs") as an initial manifestation of hemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504339" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pediatric ITP: is it different from adult ITP?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325604" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846889" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : International consensus report on the investigation and management of primary immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113906" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Childhood immune thrombocytopenic purpura: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31030811" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : von Willebrand Disease in Pediatrics: Evaluation and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16643424" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bruising and bleeding in infants and children--a practical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29198540" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Severity and Features of Epistaxis in Children with a Mucocutaneous Bleeding Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33852003" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Validation of a Clinical Decision Rule to Predict Abuse in Young Children Based on Bruising Characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27449675" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patterns of bruising in preschool children with inherited bleeding disorders: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481722" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28534860" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hemophilia Care in the Pediatric Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34327828" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217066" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hereditary Hemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28350321" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25568817" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bleeding risks associated with herbal medicine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25568817" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bleeding risks associated with herbal medicine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36304597" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dietary supplements and bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111864" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Drugs that affect platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16493500" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Developmental haemostasis. Impact for clinical haemostasis laboratories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880137" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6422167" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110927" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : EDTA-induced platelet aggregation can be avoided by a new anticoagulant also suitable for automated complete blood count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312365" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Factor XI deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181036" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Factor VII Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759690" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Superwarfarin poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31350816" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305539" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A diagnostic challenge: mild hemophilia B with normal activated partial thromboplastin time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460037" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291723" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diagnostic approach to platelet function disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21294245" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Platelet disorders in children: A diagnostic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26968829" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : New Insights Into the Treatment of Glanzmann Thrombasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929303" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bernard-Soulier syndrome: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278172" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Congenital disorders associated with platelet dysfunctions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29388750" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177606" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34027290" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fibrinolysis and bleeding of unknown cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25753785" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year 'real-world' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18034764" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624461" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
